Autopsy report · NCT01980888
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 311 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Idelalisib; Bendamustine; Rituximab; Placebo
- Participants
- 311
- Sites
- 91
- Countries
- Australia, Belgium, Canada, Croatia, Czechia, France, Hungary, Italy, Poland, Romania, Spain, United Kingdom and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.